Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CUE Stock Summary
In the News
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will take part in a fireside chat at the JMP Securities Hematology and Oncology Summit being held virtually from December 5-6, 2023.
Cue Biopharma, Inc. (CUE) Q3 2023 Earnings Call Transcript
Cue Biopharma, Inc. (NASDAQ:CUE ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Daniel Passeri - CEO Matteo Levisetti - Chief Medical Officer Anish Suri - President & Chief Scientific Officer Kerri-Ann Millar - CFO Conference Call Participants Reni Benjamin - JMP Securities Ted Tenthoff - Piper Sandler Operator Good afternoon, ladies and gentlemen, and welcome to the Cue Biopharma Third Quarter 2023 Earnings Call. At this time, all lines are in listen-only mode.
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will participate in three investor conferences this November, the Stifel Healthcare Conference, to be held in New York from November 14-15, the Jefferies London Healthcare Conference, to be held in London from November 14-16, and the Piper Sandler Annual Healthcare Conference, to be held in New York from November 28-30.
Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Call Transcript
Cue Biopharma, Inc. (NASDAQ:CUE ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Dan Passeri - Chief Executive Officer Anish Suri - President & Chief Scientific Officer Matteo Levisetti - Chief Medical Officer Kerri Millar - Chief Financial Officer Conference Call Participants Ted Tenthoff - Piper Sandler Ren Benjamin - JMP Securities Operator Greetings, and welcome to the Cue Biopharma Investor Update Call. At this time, all participants are in a listen-only mode.
3 Biotech Stocks to Buy as Companies Ink Major Deals
With patent expirations around the corner, some of the biggest pharmaceutical and biotech companies will soon face generic competition, creating a big opportunity for these top biotech stocks to buy. In 2023 alone, pharmaceutical and biotech companies spent about $85 billion on acquisitions.
Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that it will present at the Jefferies Global Healthcare Conference being held June 7–9, 2023 in New York.
3 Biotech Stocks Sitting on Huge-Upside Catalysts
Now is a great time to start accumulating top biotech stocks. The biotech boom is red-hot.
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held at the New York Hilton Midtown, May 15-16, 2023.
7 High-Potential Penny Stocks in the Biotech Sector
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ: AXSM ), for example.
Cue Biopharma, Inc. (CUE) Q4 2022 Earnings Call Transcript
Cue Biopharma, Inc. (NASDAQ:CUE ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Dan Passeri - CEO Matteo Levisetti - Chief Medical Officer Ken Pienta - Clinical Advisory Anish Suri - President and Chief Scientific Officer Kerri Millar - CFO Sara Pai - Surgical Oncologist and Director, Translational Head and Neck Cancer Research, Mass General Hospital Conference Call Participants Ted Tenthoff - Piper Sandler Ren Benjamin - JMP Securities Mark Breidenbach - Oppenheimer Stephen Willey - Stifel Operator Greetings, and welcome to the Cue Biopharma Fourth Quarter and Full Year 2022 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.
CUE Financial details
CUE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.06 | 0.16 | 0.11 | 0.48 | 0.03 | |
Net income per share | -1.94 | -1.66 | -1.56 | -1.41 | -1.48 | |
Operating cash flow per share | -1.31 | -1.4 | -1.13 | -1.24 | -1.17 | |
Free cash flow per share | -1.4 | -1.4 | -1.15 | -1.27 | -1.18 | |
Cash per share | 1.95 | 2.7 | 2.96 | 2.06 | 2.14 | |
Book value per share | 1.69 | 2.48 | 2.75 | 2.09 | 1.84 | |
Tangible book value per share | 1.69 | 2.48 | 2.75 | 2.09 | 1.84 | |
Share holders equity per share | 1.69 | 2.48 | 2.75 | 2.09 | 1.84 | |
Interest debt per share | 0 | 0.26 | 0.25 | 0.32 | 0.56 | |
Market cap | 94.63M | 349.91M | 358.89M | 353.84M | 101.6M | |
Enterprise value | 73.83M | 311.42M | 291.17M | 299.52M | 69.3M | |
P/E ratio | -2.43 | -9.53 | -8.01 | -8.01 | -1.92 | |
Price to sales ratio | 82.82 | 101.19 | 113.78 | 23.68 | 81.59 | |
POCF ratio | -3.58 | -11.36 | -11.04 | -9.11 | -2.43 | |
PFCF ratio | -3.35 | -11.34 | -10.85 | -8.9 | -2.42 | |
P/B Ratio | 2.79 | 6.41 | 4.55 | 5.4 | 1.55 | |
PTB ratio | 2.79 | 6.41 | 4.55 | 5.4 | 1.55 | |
EV to sales | 64.62 | 90.06 | 92.31 | 20.05 | 55.65 | |
Enterprise value over EBITDA | -1.95 | -8.47 | -6.62 | -6.85 | -1.37 | |
EV to operating cash flow | -2.8 | -10.11 | -8.96 | -7.71 | -1.66 | |
EV to free cash flow | -2.61 | -10.1 | -8.8 | -7.54 | -1.65 | |
Earnings yield | -0.41 | -0.1 | -0.12 | -0.12 | -0.52 | |
Free cash flow yield | -0.3 | -0.09 | -0.09 | -0.11 | -0.41 | |
Debt to equity | 0 | 0.11 | 0.09 | 0.15 | 0.29 | |
Debt to assets | 0 | 0.08 | 0.07 | 0.12 | 0.21 | |
Net debt to EBITDA | 0.55 | 1.05 | 1.54 | 1.24 | 0.64 | |
Current ratio | 6.53 | 5.24 | 5.36 | 5.35 | 6.68 | |
Interest coverage | 0 | 0 | 0 | 0 | -74.56 | |
Income quality | 0.68 | 0.84 | 0.73 | 0.88 | 0.79 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 9.89 | 3.68 | 4.64 | 1.16 | 12.98 | |
Research and developement to revenue | 24.98 | 7.95 | 10.63 | 2.77 | 30.98 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.07 | 0 | 0.02 | 0.02 | 0 | |
Capex to revenue | -1.62 | -0.01 | -0.19 | -0.06 | -0.14 | |
Capex to depreciation | -2.44 | -0.01 | -0.56 | 0.51 | -0.09 | |
Stock based compensation to revenue | 6.28 | 1.89 | 3.32 | 0.77 | 7.63 | |
Graham number | 8.57 | 9.63 | 9.83 | 8.15 | 7.84 | |
ROIC | -1.16 | -0.56 | -0.49 | -0.52 | -0.56 | |
Return on tangible assets | -0.86 | -0.51 | -0.45 | -0.53 | -0.58 | |
Graham Net | 1.38 | 2.29 | 2.28 | 1.56 | 1.42 | |
Working capital | 34.39M | 49.37M | 71.21M | 55.68M | 65.64M | |
Tangible asset value | 33.97M | 54.57M | 78.91M | 65.49M | 65.68M | |
Net current asset value | 29.22M | 44M | 66.91M | 50.56M | 51.59M | |
Invested capital | 0 | 0.11 | 0.09 | 0.15 | 0.29 | |
Average receivables | 426.19K | 377.45K | 1.09M | 2.28M | 1.6M | |
Average payables | 1.68M | 1.46M | 1.48M | 2.33M | 2.66M | |
Average inventory | 112.75K | 7.56M | 7.56M | 0.5 | 1 | |
Days sales outstanding | 0 | 79.68 | 164.02 | 76.77 | 16.78 | |
Days payables outstanding | 0 | 11.72 | 22.53 | -531.84 | 551.95 | |
Days of inventory on hand | 0 | 200.77 | 0 | 0 | 0 | |
Receivables turnover | 0 | 4.58 | 2.23 | 4.75 | 21.75 | |
Payables turnover | 0 | 31.14 | 16.2 | -0.69 | 0.66 | |
Inventory turnover | 0 | 1.82 | 0 | -1.78M | 1.81M | |
ROE | -1.15 | -0.67 | -0.57 | -0.67 | -0.8 | |
Capex per share | -0.09 | 0 | -0.02 | -0.03 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0.03 | 0.05 | |
Net income per share | -0.31 | -0.41 | -0.3 | -0.29 | -0.24 | |
Operating cash flow per share | -0.19 | -0.29 | -0.24 | -0.23 | -0.17 | |
Free cash flow per share | -0.2 | -0.29 | -0.24 | -0.23 | -0.17 | |
Cash per share | 1.67 | 2.14 | 1.48 | 1.29 | 1.18 | |
Book value per share | 1.43 | 1.84 | 1.23 | 1.03 | 0.92 | |
Tangible book value per share | 1.43 | 1.84 | 1.23 | 1.03 | 0.92 | |
Share holders equity per share | 1.43 | 1.84 | 1.23 | 1.03 | 0.92 | |
Interest debt per share | 0.56 | 0.55 | 0.43 | 0.41 | 0.36 | |
Market cap | 78.91M | 101.6M | 159.41M | 163.52M | 106.62M | |
Enterprise value | 68.79M | 69.3M | 121.79M | 128.66M | 68.31M | |
P/E ratio | -1.81 | -1.76 | -3.02 | -3.1 | -2.42 | |
Price to sales ratio | 1.16K | 671.84 | 852.45 | 118.32 | 50.77 | |
POCF ratio | -11.48 | -9.66 | -14.72 | -15.77 | -13.67 | |
PFCF ratio | -11.35 | -9.66 | -14.71 | -15.77 | -13.67 | |
P/B Ratio | 1.55 | 1.55 | 2.9 | 3.55 | 2.5 | |
PTB ratio | 1.55 | 1.55 | 2.9 | 3.55 | 2.5 | |
EV to sales | 1.01K | 458.26 | 651.3 | 93.1 | 32.53 | |
Enterprise value over EBITDA | -6.68 | -5.07 | -10.27 | -10.63 | -6.93 | |
EV to operating cash flow | -10.01 | -6.59 | -11.24 | -12.41 | -8.76 | |
EV to free cash flow | -9.9 | -6.59 | -11.24 | -12.41 | -8.76 | |
Earnings yield | -0.14 | -0.14 | -0.08 | -0.08 | -0.1 | |
Free cash flow yield | -0.09 | -0.1 | -0.07 | -0.06 | -0.07 | |
Debt to equity | 0.39 | 0.29 | 0.34 | 0.39 | 0.38 | |
Debt to assets | 0.26 | 0.21 | 0.23 | 0.25 | 0.24 | |
Net debt to EBITDA | 0.98 | 2.36 | 3.17 | 2.88 | 3.88 | |
Current ratio | 6.04 | 6.68 | 4.98 | 3.74 | 3.34 | |
Interest coverage | -88.96 | -41.43 | -36.16 | -58.26 | -39.93 | |
Income quality | 0.63 | 0.72 | 0.83 | 0.79 | 0.71 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 51.88 | 24.49 | 22.33 | 3.07 | 1.74 | |
Research and developement to revenue | 111.34 | 74.93 | 50.22 | 7.71 | 4.7 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0 | 0 | 0 | 0 | |
Capex to revenue | -1.15 | 0 | -0.01 | 0 | 0 | |
Capex to depreciation | -0.14 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 30.35 | 13.96 | 10.68 | 1.47 | 0.99 | |
Graham number | 3.15 | 4.1 | 2.86 | 2.61 | 2.22 | |
ROIC | -0.14 | -0.16 | -0.16 | -0.2 | -0.18 | |
Return on tangible assets | -0.14 | -0.16 | -0.16 | -0.18 | -0.16 | |
Graham Net | 0.97 | 1.42 | 0.89 | 0.7 | 0.64 | |
Working capital | 51.48M | 65.64M | 54.95M | 44.63M | 40.31M | |
Tangible asset value | 50.76M | 65.68M | 55.02M | 46M | 42.67M | |
Net current asset value | 36.16M | 51.59M | 42.09M | 33.78M | 31.3M | |
Invested capital | 0.39 | 0.29 | 0.34 | 0.39 | 0.38 | |
Average receivables | 766K | 426.63K | 126.63K | 665.5K | 1.4M | |
Average payables | 1.81M | 2.39M | 2.44M | 2.25M | 2.42M | |
Average inventory | 0 | 0.5 | 1 | 1 | 0.5 | |
Days sales outstanding | 1.05K | 34.07 | 94.33 | 73.91 | 71.19 | |
Days payables outstanding | 341.47 | 423.75 | 219.99 | 250.05 | 260.44 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.09 | 2.64 | 0.95 | 1.22 | 1.26 | |
Payables turnover | 0.26 | 0.21 | 0.41 | 0.36 | 0.35 | |
Inventory turnover | 0 | 580.06K | 880K | 848K | 0 | |
ROE | -0.21 | -0.22 | -0.24 | -0.29 | -0.26 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
CUE Frequently Asked Questions
What is Cue Biopharma, Inc. stock symbol ?
Cue Biopharma, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol CUE
Is Cue Biopharma, Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $6.5. The lowest prediction is $6 and the highest is $7
What is CUE stock prediction ?
With a median analyst target price of $6, 1 stock analysts have made 1 forecasts in last 90 days. $6 is the lowest and $6 is the greatest projection.
What is Cue Biopharma, Inc. stock quote today ?
Cue Biopharma, Inc. stock price is $1.84 today.
Is Cue Biopharma, Inc. stock public?
Yes, Cue Biopharma, Inc. is a publicly traded company.